174 related articles for article (PubMed ID: 33151105)
1. Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
Fischer C; Munks MW; Hill AB; Kroczek RA; Bissinger S; Brand V; Schmittnaegel M; Imhof-Jung S; Hoffmann E; Herting F; Klein C; Knoetgen H
MAbs; 2020; 12(1):1834818. PubMed ID: 33151105
[TBL] [Abstract][Full Text] [Related]
2. A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.
Schmittnaegel M; Hoffmann E; Imhof-Jung S; Fischer C; Drabner G; Georges G; Klein C; Knoetgen H
Mol Cancer Ther; 2016 Sep; 15(9):2130-42. PubMed ID: 27353170
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
4. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
5. A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo.
Carey B; DeLay M; Strasser JE; Chalk C; Dudley-McClain K; Milligan GN; Brunner HI; Thornton S; Hirsch R
Clin Immunol; 2005 Jul; 116(1):65-76. PubMed ID: 15925833
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model.
Wang J; Wang X; Chen Y; Wan M; Xiang Z; Wu X; Wei H; Wang L; Zhang P; Wang L; Yu Y
Tumour Biol; 2013 Feb; 34(1):193-201. PubMed ID: 23055194
[TBL] [Abstract][Full Text] [Related]
7. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
[TBL] [Abstract][Full Text] [Related]
8. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
Li H; Ou X; Xiong J
Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself.
Schlingmann TR; Rininsland FH; Bartholomae WC; Kuekrek H; Lehmann PV; Tary-Lehmann M
Clin Immunol; 2009 Oct; 133(1):45-51. PubMed ID: 19589730
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8
Jung K; Son MJ; Lee SY; Kim JA; Ko DH; Yoo S; Kim CH; Kim YS
Mol Cancer; 2022 Apr; 21(1):102. PubMed ID: 35459256
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response.
Knittel D; Gadzinski A; Hua S; Denizeau J; Savatier A; de la Rochère P; Boulain JC; Amigorena S; Piaggio E; Sedlik C; Léonetti M
Vaccine; 2016 Jun; 34(27):3093-3101. PubMed ID: 27154391
[TBL] [Abstract][Full Text] [Related]
13. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
14. Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules.
Schmittnaegel M; Levitsky V; Hoffmann E; Georges G; Mundigl O; Klein C; Knoetgen H
Cancer Immunol Res; 2015 Jul; 3(7):764-76. PubMed ID: 25691327
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
17. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of immunogenic determinants by the same cellular immunogen is required for the optimum immunotherapeutic benefit in mice with melanoma.
Xu W; de Zoeten E; Carr-Brendel V; Cohen EP
Cancer Immunol Immunother; 1998 Jan; 45(5):217-24. PubMed ID: 9439644
[TBL] [Abstract][Full Text] [Related]
19. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
20. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
